プラノバは、これまでに300以上の論文に紹介されています。
仕様、膜構造及びメカニズム、その他トピックスの論文の別刷りの一部をご用意いたしております。ご希望の方は、お気軽にお問い合わせください。

• Case Studies
• TSE
• Basics

In vitro study of a triple-secured von Willebrand factor concentrate Mazurier, C., et al.
Laboratoire Francais du Franctionnement et des Biotechnologies
Vox Sanguinis 86: 100-104 (2004).

Virus removal from hemoglobin solution using Planova Membrane Naito, Y., et al.
Waseda University, Hokkaido Red Cross, and Tokyo Medical University
Journal of Artificial Organs 5: 141-145 (2002).

Inactivation and Clearance of Viruses During the Manufacture of High Purity Factor IX Johnston, A., et al.
CSL Limited and Macfarlane Burnet Centre for Medical Research
Biologicals 28: 129-136 (2000).

Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration Troccoli, N., et al.
Massachusetts Biologic Laboratories and Biologic Research Faculty and Facility
Biologicals 26: 321-329 (1998).

Virus Removal Studies Using Nanofiltration Membranes O'Grady, J., et al.
MedImmune, Inc. and Biological Research Faculty and Facility
Dev Biol Stand. 88: 319-326 (1996).

Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration Maerz, H., et al.
University of Leipzig, Humboldt-University/Charite, and Asahi Chemical Industry
Nature Biotechnology 14: 651-652 (1996).

Manufacturing process of Anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance Morrica, A., et al.
Kedrion S.p.A. and Q-ONE Biotech Ltd
Biologicals 31: 165-173 (2003).

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity Poelsler, G., et al.
Baxter Bioscience
Vox Sanguinis 94: 184-192 (2008).

Large-scale production and properties of human plasma-derived activated Factor VII concentrate Tomokiyo, K., et al.
Kaketsuken) Vox Sanguinis 84: 54-64 (2003).

Implementation of a 20-nm pore-size filter in the plasma-derived Factor VIII manufacturing process Furuya, K., et al.
Japanese Red Cross Plasma Fractionation Center
Vox Sanguinis 91: 119-125 (2006).

Viral safety of Nanogam^R, a new 15 nm-filtered liquid immunoglobulin product Terpstra, F., et al.
Sanquin and Finnish Red Cross Blood Service
Vox Sanguinis 90: 21-32 (2006).

A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates Chtourou, S., et al.
LFB and NIBSC
Vox Sanguinis 92: 327-337 (2007).

Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives Kreil, T., et al.
Baxter BioScience
Transfusion 46: 1143-1151 (2006).

Clearance of dengue virus in the plasma-derived therapeutic proteins Xie, Y., et al.
Advantek Serum Laboratories Limited and The Chinese University of Hong Kong
Transfusion 48: 1342-1347 (2008).

Development of a Highly Purified Multicomponent Leukocyte IFN-α Product Tölö, H., et al.
Finnish Red Cross Blood Transfusion Service and Biomedical Center
Journal of Interferon and Cytokine Research 21: 913-920 (2001).

Nanofiltration of single plasma donations: feasibility study Burnouf, T., et al.
Human Plasma Product Services, Asahi Kasei Corporation, El-Shabrawishy Blood Bank, Cairo University, and St Thomas' Hospital
Vox Sanguinis 84: 111-119 (2003).

A Two-Column Process to Purify Antibodies Without Protein A Ferreira, G., et al.
Medarex, Inc.
BioPharm International (2007).

Virus Filtration of High-Concentration Monoclonal Antibody Solutions Marques, B., et al.
Merck and Co., Inc.
Biotechnology Progress 25: 483-491 (2009).

Effect of Antibody Solution Conditions on Filter Performance for Virus Removal Filter Planova™ 20N Hongo-Hirasaki, T., et al.
Asahi Kasei Medical Co., Ltd.
Biotechnology Progress 26: 1080-1087 (2010).

Effects of Varying Virus-Spiking Conditions on a Virus-Removal Filter Planova™ 20N in a Virus Validation Study of Antibody Solutions Hongo-Hirasaki, T., et al.
Asahi Kasei Medical Co., Ltd.
Biotechnology Progress 27: 162-169 (2011).

ページの先頭に戻る

Scrapie Removal using Planova™ Virus Removal Filters Tateishi, J., et al.
Kyushu University, Tohoku University, Asahi Kasei Corporation, and Inveresk Research
Biologicals 29: 17-25 (2001).

Removal of Causative Agent of Creutzfeldt-Jakob Disease (CJD) through Membrane Filtration Method Tateishi, J., et al.
Kyushu University and Asahi Chemical Industry
Membrane 18(6): 357-362 (1993).

Prion removal by nanofiltration under different experimental conditions Yunoki, M., et al.
Osaka University, Benesis Corporation, Mitsubishi Pharma Corporation, and Invitrogen BioServices
Biologicals 36: 27-36 (2008).

Current strategies to prevent transmission of prions by human plasma derivatives Burnouf, T., et al.
Human Plasma Product Services and World Health Organization
Transfusion Clinique et Biologique 13: 320-328 (2006).

Type 1 and type 2 human PrPSc have different aggregation sizes in methioine homozygotes with sporadic, iatrogenic and variant Creutzfeldt-Jakob disease Kobayashi, A., et al.
Tohoku University, Asahi Kasei Pharma Corporation, University of Edinburgh, and Kyushu University
Journal of General Virology 86: 237-240 (2005).

ページの先頭に戻る

Rejection of single stranded and double stranded DNA by porous hollow fiber membranes Higuchi, A., et al.
Seikei University, Asahi Chemical Industry, and Fukuoka Women's University
Journal of Membrane Science 116: 191-197 (1996).

Removal of small viruses (parvovirus) from IgG solution by virus removal filter Planova™ 20N Hongo, T., et al.
Asahi Kasei Medical Co., Ltd. and Yamaguchi University
Journal of Membrane Science 278: 3-9 (2006).

Electron microscopic estimation of removal of parvovirus B19 (HPVB19) by nanofiltration with a novel filter membrane Yamaguchi, K., et al.
Yamaguchi University, Fujirebio Inc., Takahashi Children's Clinic, and Hokkaido Red Cross Blood Center
Journal of Membrane Science 298: 99-109 (2007).

Phage passage after extended processing in small-virus-retentive filters Lute, S., et al.
Food and Drug Administration and Eli Lilly and Company
Biotechnol. Appl. Biochem. 47: 141-151 (2007).

Nanofiltration of plasma-derived biopharmaceutical products Burnouf, T., et al.
Human Plasma Product Service
Haemophilia 9: 24-37 (2003).

ページの先頭に戻る